journal
MENU ▼
Read by QxMD icon Read
search

Hematology/oncology and Stem Cell Therapy

journal
https://www.readbyqxmd.com/read/29729225/diagnostic-utility-of-glycosyltransferase-mrna-expression-in-gastric-cancer
#1
Showkat Ahmad Bhat, Manzoor Ur Rahman Mir, Sabhiya Majid, Tehseen Hassan, Muneeb U Rehman, Sonallah Kuchy
OBJECTIVE/BACKGROUND: Posttranslational modification of proteins, including glycosylation, is known to differ between normal and tumor cells. Altered glycosyltransferase levels have been observed in tumor tissues and their role in tumor metastasis and invasion has been implicated. In this study the role of altered glycosyltransferase messenger RNA (mRNA) levels in serum of gastric cancer patients as early markers of gastric cancer was evaluated. METHODS: In this case control study the expression profile of ppGalNAc-T6, GlcNAcT-V, ST3Gal I, ST3 Gal IV, and ST6GalNAc-I in normal healthy control and gastric cancer patients was compared...
April 27, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29705567/intravenous-compared-to-oral-busulfan-with-cyclophosphamide-for-autologous-hematopoietic-cell-transplant-conditioning-for-plasma-cell-myeloma
#2
Moaath Mustafa Ali, Donna M Corrigan, Lisa A Rybicki, Melissa A Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J Bolwell, Navneet S Majhail, Ronald Sobecks
No abstract text is available yet for this article.
April 24, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29705566/vinorelbine-cyclophosphamide-compared-to-cyclophosphamide-in-peripheral-blood-stem-cell-mobilization-for-multiple-myeloma
#3
Sanjay de Mel, Yunxin Chen, Adeline Lin, Teck Guan Soh, Melissa Ooi, Eng Soo Yap, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Joanna Mah, Karen Lim, Li Mei Poon, Belinda Tan, Yelly, Hui Li Lim, Liang Piu Koh, Bee Choo Tai, Zhaojin Chen, Wee Joo Chng, Satish Kumar Gopalakrishnan, Lip Kun Tan
BACKGROUND: High dose Cyclophosphamide (Cy) and Vinorelbine Cyclophosphamide (Vino-Cy) are stem cell (SC) mobilisation options for patients with multiple myeloma (MM). We present a comparison of mobilisation outcomes using these regimens. PATIENTS AND METHODS: Vino-Cy patients received Vinorelbine 25 mg/m2 on day 1, cyclophosphamide 1500 mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10 mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000 mg/m2 on day 1 and GCSF10 mcg/kg/day from day 5 onwards...
April 23, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29684342/the-relation-between-protein-z-polymorphism-and-the-risk-of-thrombosis-in-egyptian-patients-with-antiphospholipid-syndrome
#4
Yomna K Eissa, Hend N Ellithy, Sherif M Yousry, Zakaria Ismail
BACKGROUND: The genetic background plays an important role in thrombosis and pregnancy morbidities. Low levels of protein Z is associated with increased risk of thrombosis. The G79A polymorphism in the protein Z gene may be a genetic risk factor for thrombosis. AIM OF THE STUDY: To investigate the prevalence and clinical significance of the protein Z-79 G/A gene polymorphism in Egyptian patients with antiphospholipid syndrome (APS). METHODS: We genotyped 60 APS patients and 41 controls, for protein Z-79 G/A gene polymorphism using the PCR-restriction fragment length...
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29684341/predictors-of-outcome-in-patients-with-hematologic-malignancies-admitted-to-the-intensive-care-unit
#5
Nassar Al-Zubaidi, Emad Shehada, Khaled Alshabani, Jihane ZazaDitYafawi, Pascal Kingah, Ayman O Soubani
PURPOSE: Several studies showed conflicting results about prognosis and predictors of outcome of critically ill patients with hematological malignancies (HM). The aim of this study is to determine the hospital outcome of critically ill patients with HM and the factors predicting the outcome. METHODS AND MATERIALS: All patients with HM admitted to MICU at a tertiary academic medical center were enrolled. Clinical data upon admission and during ICU stay were collected...
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29684340/myeloid-sarcoma-with-megakaryoblastic-differentiation-presenting-as-a-breast-mass
#6
Ifeyinwa E Obiorah, Metin Ozdemirli
Myeloid sarcoma is an extramedullary tumor that consists of myeloblasts or immature myeloid cells. The neoplasm can occur in any part of the body, including the bone, periosteum, lymph nodes, skin, and soft tissue and they may occur de novo or in association with acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes. Most cases display a myelomonocytic or pure monoblastic morphology. Tumors with megakaryoblastic differentiation are extremely uncommon and may occur in association with transformation of a myeloproliferative disorder...
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29684339/sorafenib-induced-tumor-lysis-syndrome-in-a-patient-with-metastatic-hepatocellular-carcinoma
#7
Sardar Zakariya Imam, Mohammad Faizan Zahid, Muhammad Asad Maqbool
Tumor lysis syndrome is a potentially lethal complication of chemotherapy, usually associated with aggressive hematologic malignancies. We describe the case of a young patient with metastatic hepatocellular cancer who developed rapid and fatal tumor lysis syndrome following initiation of sorafenib therapy. Although rare with sorafenib therapy for hepatocellular carcinoma, tumor lysis syndrome is serious complication. Patients with a high burden of disease at therapy initiation should have their metabolic parameters measured prior to starting therapy and closely followed for the first 1-2 weeks while being treated...
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29684338/plasma-cell-myeloma-with-auer-rode-like-inclusions
#8
Nour AlMozain, Tarek Owaidah
No abstract text is available yet for this article.
April 17, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29559300/allogeneic-stem-cell-transplantation-for-relapsed-primary-central-nervous-system-lymphoma-is-it-feasible
#9
Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz Bozdag
Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT...
March 16, 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29100977/evaluation-of-weekly-paclitaxel-plus-carboplatin-followed-by-anthracycline-chemotherapy-on-the-neoadjuvant-treatment-of-patients-with-triple-negative-breast-cancer
#10
Aurelio B Castrellon, Michel Velez, Steven M Nguyen, Marcelo Blaya, Sandra Barnick, Katerine Dumais, Nicholas LeCroy, Luis E Raez
OBJECTIVE: To evaluate the effectiveness and tolerability of neoadjuvant chemotherapy with weekly paclitaxel in combination with weekly carboplatin area under curve 2 followed by anthracycline chemotherapy. PATIENTS AND METHODS: This is a retrospective review of electronic medical records of patients (N = 32) with stage 1c-III triple-negative breast cancer. Patients received neoadjuvant chemotherapy with paclitaxel 80 mg/m2 once per week for 12 weeks in combination with carboplatin area under curve 2 once per week for 12 weeks (wP + wCb), followed by a standard anthracycline regimen including either doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks, or epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for four cycles with myeloid growth factor support...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29079126/successful-treatment-of-pure-red-cell-aplasia-with-high-dose-dexamethasone-after-abo-incompatible-allogeneic-hematopoietic-stem-cell-transplantation
#11
Rosario Varela Gómez, Goretti Vázquez Vázquez, Victor Noriega Concepción, Andrea Galego García, Concepción Andón Saavedra
The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition.
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28830802/impact-of-vitamin-d-deficiency-on-increased-blood-eosinophil-counts
#12
João Tadeu Damian Souto Filho, Alícia Souza de Andrade, Felipe Mesquita Ribeiro, Paola de Araujo Sardenberg Alves, Virgínia Ribeiro Fernandes Simonini
OBJECTIVE/BACKGROUND: Vitamin D has been increasingly recognized as an immunomodulatory agent. Its deficiency has been associated with immune-mediated diseases such as asthma, rhinitis, and atopic dermatitis. These allergic conditions are dependent on T-helper type 2 (Th2) cells secreting interleukins, overproduction of immunoglobulin E (IgE), and eosinophil activation. We investigated the association between serum vitamin D levels and blood absolute eosinophil count. METHODS: We carried out a cross-sectional study of 669 men and women referred to a clinical pathology laboratory who underwent 25-hydroxyvitamin D testing and complete blood count analysis on the same day...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28648946/end-of-therapy-minimal-residual-disease-mrd-measurement-in-children-with-all-does-not-predict-relapse
#13
Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris Madanat
No abstract text is available yet for this article.
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28641093/hematological-parameters-and-red-blood-cell-morphological-abnormality-of-glucose-6-phosphate-dehydrogenase-deficiency-co-inherited-with-thalassemia
#14
Jutharat Pengon, Saovaros Svasti, Sumalee Kamchonwongpaisan, Phantip Vattanaviboon
OBJECTIVE/BACKGROUND: Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and thalassemia are genetically independent hemolytic disorders. Co-inheritance of both disorders may affect red blood cell pathology to a greater extent than normally seen in either disorder alone. This study determines the prevalence and evaluates hematological changes of G-6-PD deficiency and thalassemia co-inheritance. METHODS: G-6-PD deficiency was screened from 200 male thalassemia blood samples using a fluorescent spot test...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28633037/treatment-with-methotrexate-rituximab-and-cytosine-arabinoside-followed-by-autologous-stem-cell-transplantation-in-primary-central-nervous-system-lymphoma-a-single-center-experience
#15
Pinar Ataca Atilla, Erden Atilla, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Selami Kocak Toprak, Pervin Topcuoglu, Taner Demirer, Osman Ilhan, Onder Arslan, Gunhan Gurman, Muhit Ozcan
OBJECTIVE/BACKGROUND: Primary central nervous system lymphoma (PCNSL) is associated with worst prognosis compared with other aggressive non-Hodgkin's lymphomas. However, recent trials have demonstrated that long-term progression-free survival can be achieved by immunochemotherapy. Our goal is to present our experience in aggressive PCNSL in this study. METHODS: We retrospectively evaluated the clinical features and management of 13 PCNSL patients who were diagnosed and treated between 2006 and 2015...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28549767/treatment-of-del17p-and-or-aberrant-tp53-chronic-lymphocytic-leukemia-in-the-era-of-novel-therapies
#16
REVIEW
Hind Rafei, Mohamed A Kharfan-Dabaja
More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton's tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibitor of BCL-2 known to play an important role in regulating cell death, has been approved recently for treatment of patients with chronic lymphocytic leukemia with Del17p who have received at least one prior therapy...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28460209/low-fixed-dose-defibrotide-in-management-of-hepatic-veno-occlusive-disease-post-stem-cell-transplantation
#17
Bhausaheb Bagal, Arun Chandrasekharan, Aliya Chougle, Navin Khattry
OBJECTIVE/BACKGROUND: Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation. Severe VOD is associated with poor long-term outcomes with very high mortality. Besides supportive care, only defibrotide has been found to be effective in the management of VOD. The recommended dose of defibrotide is 25mg/kg/d but there has been no classical dose finding study done for this drug. A higher dose of defibrotide is associated with increased risk of bleeding and this drug is prohibitively expensive...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/27614230/polycythemia-vera-masked-due-to-severe-iron-deficiency-anemia
#18
Shweta Kambali, Asma Taj
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin. We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/27514010/severe-plasmodium-vivax-cerebral-malaria-complicated-by-hemophagocytic-lymphohistiocytosis-treated-with-artesunate-and-doxycycline
#19
Sawsan Amireh, Hamid Shaaban, Gunwant Guron
Malaria-related hemophagocytic lymphohistiocytosis is a rare, potentially fatal, hyperinflammatory disease entity which can be challenging to diagnose and treat. It is usually associated with Plasmodium falciparum infection. It is less frequently associated with Plasmodium vivax. Here we report an unusual case of a 23-year-old healthy Nigerian man who presented with fever, microangiopathic hemolytic anemia, acute renal failure, and confusion, and was diagnosed as having cerebral malaria-related hemophagocytic lymphohistiocytosis caused by P...
March 2018: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29474820/effects-of-two-doses-of-anti-t-lymphocyte-globulin-fresenius-given-after-full-match-sibling-stem-cell-transplantation-in-acute-myeloblastic-leukemia-patients-who-underwent-myeloablative-fludarabine-busulfan-conditioning
#20
Can Boga, Mahmut Yeral, Ciğdem Gereklioglu, Suheyl Asma, Erkan Maytalman, Pelin Aytan, Ilknur Kozanoglu, Cagla Sariturk, Hakan Ozdogu
OBJECTIVE/BACKGROUND: Anti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection. Available clinical studies have been conducted in heterogenous patient populations and with different administration protocols including stem cell sources. Additionally, the pharmacokinetics of ATG is variable, and the clinically effective dose of rATG-F, in particular, is not exactly known...
February 20, 2018: Hematology/oncology and Stem Cell Therapy
journal
journal
41905
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"